Cochrane · systematic review · CD012501
Cerivastatin for lowering lipids
Adams, SP, Tiellet, N, Alaeiilkhchi, N, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
26
current version
GRADE rated
19
No studies
7
Included studies
NR
No studies 7 · 26.9%Ungraded 0 · 0%Very low 2 · 7.7%Low 0 · 0%Moderate 5 · 19.2%High 12 · 46.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Low‐density lipoprotein (LDL) cholesterol‐lowering efficacy of cerivastatin
Population: participants with normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cerivastatin dose | no estimate extracted | NR | No studies |
0.05 mg/d | no estimate extracted | 5 studies · 1811 participants | High |
0.1 mg/d | no estimate extracted | 11 studies · 2327 participants | High |
0.2 mg/d | no estimate extracted | 15 studies · 2498 participants | High |
0.3 mg/d | no estimate extracted | 19 studies · 3020 participants | High |
0.4 mg/d | no estimate extracted | 13 studies · 3080 participants | High |
0.8 mg/d | no estimate extracted | 6 studies · 2560 participants | High |
aMean baseline values. | no estimate extracted | NR | No studies |
Total cholesterol‐lowering efficacy of cerivastatin
Population: participants with normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cerivastatin dose | no estimate extracted | NR | No studies |
0.05 mg/d | no estimate extracted | 3 studies · 569 participants | High |
0.1 mg/d | no estimate extracted | 10 studies · 2114 participants | High |
0.2 mg/d | no estimate extracted | 14 studies · 1953 participants | High |
0.3 mg/d | no estimate extracted | 17 studies · 2567 participants | High |
0.4 mg/d | no estimate extracted | 10 studies · 2715 participants | High |
0.8 mg/d | no estimate extracted | 5 studies · 1938 participants | High |
CI: confidence interval | no estimate extracted | NR | No studies |
aMean baseline values. | no estimate extracted | NR | No studies |
Triglyceride‐lowering efficacy of cerivastatin
Population: participants with normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cerivastatin dose | no estimate extracted | NR | No studies |
0.05 mg/d | no estimate extracted | 2 studies · 504 participants | Very low Downgraded: imprecision |
0.1 mg/d | no estimate extracted | 4 studies · 731 participants | Moderate Downgraded: imprecision |
0.2 mg/d | no estimate extracted | 5 studies · 780 participants | Moderate Downgraded: imprecision |
0.3 mg/d | no estimate extracted | 8 studies · 1303 participants | Moderate Downgraded: imprecision |
0.4 mg/d | no estimate extracted | 6 studies · 1969 participants | Moderate Downgraded: imprecision |
0.8 mg/d | no estimate extracted | 4 studies · 1880 participants | Moderate Downgraded: imprecision |
CI: confidence interval | no estimate extracted | NR | No studies |
All doses of cerivastatin compared to placebo for withdrawal due to adverse events
Population: participants with normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Withdrawals due to adverse events All doses of cerivastatin vs placebo | RR 1.09 [0.68, 1.74] | 11 studies · 6570 participants | Very low Downgraded: risk of bias, imprecision |